• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada

    4/7/26 12:15:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care
    Get the next $ALC alert in real time by email
    • New partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game.

    This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407095429/en/

    Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada

    Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada

    For the estimated 8.5 million Canadians living with dry eye, symptoms such as stinging, burning, tired, irritated and watery eyes can appear during everyday activities - including watching live sports.1,4 Yet many people don't immediately recognize these symptoms as dry eye5 or realize that simple management can help them stay comfortable for the season's most memorable moments.

    As the Toronto Blue Jays celebrate their historic 50th season, fans across Canada are gearing up for everything that makes baseball iconic - sunny afternoons at the ballpark, nail-biting innings, and the big plays fans talk about long after the game ends.

    From first pitch to final out, baseball keeps fans engaged for hours at a time. Long games, bright stadium lights and extended screen viewing can quietly put extra strain on the eyes,2,3 and when dry eye sets in, it can make it harder for fans to see the action.

    "A season like this is about soaking in every moment, especially as the Blue Jays mark 50 seasons of baseball," said Vanessa Johari Hansen, Vision Care Franchise Head. Alcon Canada. "Dry eye is common and often overlooked, and it can disrupt an experience more than many people realize. Through this partnership, we're helping Canadians recognize the signs of dry eye early so they can stay comfortable for the moments that make the season unforgettable."

    "Our fans bring intense passion to every game," said Mark Ditmars, VP of Corporate Partnerships, Toronto Blue Jays. "As we celebrate this milestone season, we're excited to welcome Systane as an official partner of the Toronto Blue Jays. Together, we will raise awareness of dry eye to help ensure fans can watch our games comfortably whether they're cheering from the ballpark or from home."

    Through stadium activations, digital experiences and national awareness initiatives, the partnership will help bring the conversation around dry eye to millions of Canadian fans throughout the season - whether they're watching from the ballpark or at home.

    Effective dry eye management plays an important role in supporting visual comfort during everyday activities, including watching live sports. As the #1 doctor and pharmacist-recommended brand in the dry eye category in Canada,6 Systane is a trusted dry eye drop designed with a unique combination of ingredients to provide effective dry eye symptom relief.7-10

    As the Toronto Blue Jays celebrate five decades of unforgettable baseball moments, Systane is proud to support fans throughout the season - helping them stay comfortable so they don't miss a moment that matters.

    Important Information for the Systane® Family of Products

    Systane lubricant eye drops have been clinically proven to reduce the symptoms of dry eye, providing fast, long-lasting relief and comfort. Systane is the #1 global consumer brand of artificial tears.11 Systane COMPLETE provides multi symptom relief for all types of dry eyes.9,12,13 Systane HYDRATION gives long-lasting relief of dry eye symptoms for moderate, chronic sufferers*14,17,20 or patients recovering from cataract surgery and seeking dry eye relief.15,16 Systane® ULTRA provides fast-acting relief17,18 and is designed for dry eye with aqueous-deficient patients.18,19 Learn more at https://systane.myalcon.com/en-ca/.

    About Alcon

    Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.

    *In vitro data

    References

    1. Chan C, Ziai S, Myageri V, et al. Economic burden and loss of quality of life from dry eye disease in Canada. BMJ Open Ophthalmol. 2021;6(1):e000709. doi:10.1136/bmjophth-2021-000709.
    2. Canadian National Institute for the Blind. Dry eye. CNIB. Accessed February 24, 2026. https://www.cnib.ca/en/dry-eye.
    3. Mehra D, Galor A. Digital Screen Use and Dry Eye: A Review. Asia Pac J Ophthalmol (Phila). 2020;9(6):491-497. doi:10.1097/APO.0000000000000328.
    4. National Eye Institute. Facts about dry eye. National Institutes of Health. Published September 2015. https://www.nei.nih.gov/sites/default/files/health-pdfs/factsaboutdryeye.pdf
    5. Alcon Data on File. REF-02584. 2019.
    6. Alcon Data on File. REF-29181. 2025.
    7. Srinivasan S, Venkiteshwar M. A Decade of Effective Dry Eye Disease Management with Systane Ultra (Polyethylene Glycol/Propylene Glycol with Hydroxypropyl Guar) Lubricant Eye Drops Clin Ophthalmol. 2021;15:2421-2435. doi:10.2147/OPTH.S294427.
    8. Srinivasan S, Garofalo R, Williams R. Safe and Effective Management of Dry Eye Symptoms with Hydroxypropyl Guar and Hyaluronic Acid Dual-Polymer Lubricating Eye Drops: A Review of Preclinical and Clinical Studies Clin Ophthalmol. 2023;17:3883-3898. doi:10.2147/OPTH.S428725/
    9. Bickle K, Miller JR, Tauber J, Awisi-Gyau D. Multi-symptom relief with Propylene Glycol-Hydroxypropyl-Guar Nanoemulsion lubricant eye drops in subjects with dry eye disease: A post-marketing prospective study. Ophthalmol Ther. 2024;13(2):481-494. doi:10.1007/s40123-023-00853-3
    10. Springs CL. Novel ocular lubricant containing an intelligent delivery system: details of its mechanism of action. In: Baudouin C, Aragona P, eds. Developments in Ophthalmology. Vol 45. Basel, Switzerland: Karger; 2010:139-147.
    11. Alcon Data on File. REF-19808. 2025.
    12. Silverstein S, Yeu E, Tauber J, Guillon M, Jones L, Galarreta D, et al. Symptom relief following a single dose of propylene glycol–hydroxypropyl guar nanoemulsion in patients with dry eye disease: a phase IV, multicenter trial. Clin Ophthalmol. 2020;14:3167-3177. doi:10.2147/OPTH.S263362
    13. Alcon Data on File. REF-20875. 2023.
    14. Rolando M, Autori S, Badino F, Barabino S. Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar–containing ocular lubricant in a population of dry eye patients. J Ocul Pharmacol Ther. 2009;25(3):271-278. doi:10.1089/jop.2008.0026
    15. Alcon Data on File. REF-23974. 2024.
    16. Alcon Data on File. REF-23973. 2024
    17. Davitt WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther. 2010;26(4):347-353. doi:10.1089/jop.2010.0025.
    18. Aguilar A, Berra M, Trédicce J, Berra A. Efficacy of polyethylene glycol–propylene glycol–based lubricant eye drops in reducing squamous metaplasia in patients with dry eye disease. Clin Ophthalmol. 2018;12:1443-1449. doi:10.2147/OPTH.S164888.
    19. Moon SW, Hwang JH, Chung SH, Nam KH. The impact of artificial tears containing hydroxypropyl guar on the mucous layer. Cornea. 2010;29(12):1430-1435.
    20. Rangarajan R, Kraybill B, Ogundele A, Ketelson HA. Effects of a hyaluronic acid/hydroxypropyl guar artificial tear solution on protection, recovery, and lubricity in models of corneal epithelium. J Ocul Pharmacol Ther. 2015;31(8):491-497. doi:10.1089/jop.2014.0164

    Connect with us on

    Facebook

    LinkedIn

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260407095429/en/

    Media Relations

    Alcon United States

    Luiza Barros

    [email protected]

    NATIONAL Public Relations Canada (for Alcon)

    Sasha Sheludko

    [email protected]

    Get the next $ALC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALC

    DatePrice TargetRatingAnalyst
    2/26/2026$97.00Equal Weight → Overweight
    Wells Fargo
    1/30/2026Mkt Perform
    William Blair
    1/20/2026Hold → Buy
    Deutsche Bank
    1/9/2026Buy → Hold
    Stifel
    12/11/2025$75.00Buy → Underperform
    BofA Securities
    8/21/2025Overweight → Neutral
    Analyst
    5/20/2025Buy → Hold
    Deutsche Bank
    5/14/2025$102.00 → $99.00Buy
    BTIG Research
    More analyst ratings

    $ALC
    SEC Filings

    View All

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    4/2/26 4:34:32 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 6-K filed by Alcon Inc.

    6-K - ALCON INC (0001167379) (Filer)

    2/24/26 4:44:18 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form 20-F filed by Alcon Inc.

    20-F - ALCON INC (0001167379) (Filer)

    2/24/26 4:41:01 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alcon upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00

    2/26/26 7:10:22 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    William Blair initiated coverage on Alcon

    William Blair initiated coverage of Alcon with a rating of Mkt Perform

    1/30/26 6:43:20 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon upgraded by Deutsche Bank

    Deutsche Bank upgraded Alcon from Hold to Buy

    1/20/26 8:36:02 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dry Eye in Canada

    New partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game. This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407095429/en/Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dr

    4/7/26 12:15:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026

    TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across pupil sizes and lighting conditions than TECNIS Eyhance3,* At ASCRS, Alcon will also feature more than 60 scientific presentations and peer-to-peer educational symposia Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of Clareon® TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruP

    4/6/26 8:03:00 AM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Publishes Agenda for 2026 Annual General Meeting

    Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-

    4/2/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Leadership Updates

    Live Leadership Updates

    View All

    Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

    Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha

    11/10/25 8:00:00 AM ET
    $ALC
    $STAA
    Ophthalmic Goods
    Health Care

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $ALC
    Financials

    Live finance-specific insights

    View All

    Alcon Publishes Agenda for 2026 Annual General Meeting

    Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-

    4/2/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Delivers Strong Fourth-Quarter 2025 Topline Growth as New Product Launches Accelerate Sales

    Fourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated $2.3 billion of cash from operations and $1.7 billion of free cash flow3 in full-year 2025 Returned $848 million to shareholders through share repurchases and dividends Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant curren

    2/24/26 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds

    Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c

    11/11/25 4:30:00 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    $ALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alcon Inc.

    SC 13G - ALCON INC (0001167379) (Subject)

    2/13/24 3:47:46 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/23 1:35:38 PM ET
    $ALC
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by Alcon Inc. (Amendment)

    SC 13G/A - ALCON INC (0001167379) (Subject)

    2/10/22 5:01:03 PM ET
    $ALC
    Ophthalmic Goods
    Health Care